New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication by Jennifer H. Gunter, Phoebe L. Sarkar, Amy A. Lubik, Colleen C. Nelson

“…We provide an update on current treatments for advanced prostate cancer and discuss whether metabolic dysfunction, developed during ADT, provides a unique therapeutic window for rapid translation of insulin-sensitising medication as combination therapy with antiandrogen targeting agents for the management of advanced prostate cancer.…”
Get full text

Editorial: Prostate cancer research: tools, cancer cell types, molecular targets by Hung-Ming Lam, Alvin Y. Liu

Subjects: “…prostate cancer…”
Get full text

Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers by Hua Huang, Huibo Lian, Wang Liu, Benyi Li, Runzhi Zhu, Haiyan Shao

Subjects: “…Prostate cancer…”
Get full text

Analysing DNA methylation and transcriptomic signatures to predict prostate cancer recurrence risk by Fahad M. Aldakheel, Hadeel Alnajran, Shatha A. Alduraywish, Ayesha Mateen, Mohammed S. Alqahtani, Rabbani Syed

Subjects: Get full text

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer by Lior Z. Braunstein, Ming-Hui Chen, Marian Loffredo, Philip W. Kantoff, Anthony V. D'Amico

“…Prostate Cancer…”
Get full text

Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy by Al B. Barqawi, Kevin J. Krughoff, Khadijah Eid

“…Among men, prostate cancer has a high prevalence, with relatively lower cancer-specific mortality risk compared to lung and colon cancer. …”
Get full text

The heat of the battle: inflammation’s role in prostate cancer development and inflammation-targeted therapies by Ujjawal Sharma, Anidrisha Sahu, Himanshu Shekhar, Bunty Sharma, Shafiul Haque, Damandeep Kaur, Hardeep Singh Tuli, Astha Mishra, Faraz Ahmad

Subjects: “…Prostate cancer…”
Get full text

Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer by Daniar K. Osmonov, Alexey V. Aksenov, Annkathrin Boller, Almut Kalz, Diana Heimann, Isa Janssen, Klaus-Peter Jünemann

“…Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. …”
Get full text

Central Pain and Complex Motoric Symptoms after Gosarelin Therapy of Prostate Cancer by G. Ernst, A. Gericke, P. Berg

“…A 76-year-old man with prostate cancer T3N0M0 and increasing PSA was treated with goserelin three times in a half year. …”
Get full text

Development and test of reliability and validity of the Health Belief Scale for Prostate Cancer Screening by YU Lina, LUO Cui, LIU Shuangtai, XU Huan, LI Xiaoyan, ZHANG Xiaomeng, WANG Ting

Subjects: “…prostate cancer…”
Get full text

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms by Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B. Aragon-Ching

“…Prostate Cancer…”
Get full text

Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells by Bin Han, Naohiro Fujimoto, Mizuki Kobayashi, Tetsuro Matsumoto

“…Prostate Cancer…”
Get full text

Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent by Timothy R. Rebbeck, Susan S. Devesa, Bao-Li Chang, Clareann H. Bunker, Iona Cheng, Kathleen Cooney, Rosalind Eeles, Pedro Fernandez, Veda N. Giri, Serigne M. Gueye, Christopher A. Haiman, Brian E. Henderson, Chris F. Heyns, Jennifer J. Hu, Sue Ann Ingles, William Isaacs, Mohamed Jalloh, Esther M. John, Adam S. Kibel, LaCreis R. Kidd, Penelope Layne, Robin J. Leach, Christine Neslund-Dudas, Michael N. Okobia, Elaine A. Ostrander, Jong Y. Park, Alan L. Patrick, Catherine M. Phelan, Camille Ragin, Robin A. Roberts, Benjamin A. Rybicki, Janet L. Stanford, Sara Strom, Ian M. Thompson, John Witte, Jianfeng Xu, Edward Yeboah, Ann W. Hsing, Charnita M. Zeigler-Johnson

“…Prostate Cancer…”
Get full text

Mitochondrial Cytochrome c Oxidase Subunit 1 Sequence Variation in Prostate Cancer by Takara A. Scott, Rebecca S. Arnold, John A. Petros

“…Mitochondrial DNA (mtDNA) mutations have been described in every adult neoplasm including prostate cancer. There are marked racial differences in mutations within the cytochrome c oxidase subunit 1 (COI) gene in individuals with prostate cancer (PCa). …”
Get full text

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies by Tilman Todenhöfer, Arnulf Stenzl, Lorenz C. Hofbauer, Tilman D. Rachner

“…Maintaining bone health remains a clinical challenge in patients with prostate cancer (PC) who are at risk of developing metastatic bone disease and increased bone loss due to hormone ablation therapy. …”
Get full text

Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance by Caihong Li, Dongkai Cheng, Peng Li

Subjects: “…prostate cancer…”
Get full text

29 Artificial Intelligence (AI) in the management of prostate cancer - Current state of the art by P. Dasgupta, R. Khanna, A. Granados Martinez, N. Raison, S. Ourselin, A. Briganti, F. Montorsi

Get full text

A Perspective on Withania somnifera Modulating Antitumor Immunity in Targeting Prostate Cancer by Seema Dubey, Manohar Singh, Ariel Nelson, Dev Karan

“…This article signifies the cumulative information about the role of WFA in modulating antitumor immunity and its potential in targeting prostate cancer.…”
Get full text

Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer by Alacia M. Voth, John G. Alford, Edward W. Swim

Subjects: “…prostate cancer…”
Get full text

Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer by Manish Kohli, Rui Qin, Rafael Jimenez, Scott M. Dehm

“…Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). …”
Get full text